Activation of the interferon system by short-interfering RNAs
By Carol A Sledz, Michelle Holko, M. J. Veer, R. Silverman, Bryan R. G. Williams. Nature Cell Biology, 2003
1,508 citations recorded by the source corpus.
Subfields: Immunology, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/bf0529a958d11bfbe319b6b9334aea75e693aa52
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
- Shizuo Akira
- Satoshi Uematsu
- V. Hornung
- G. Hartmann
- A. Ablasser
- Eli Gilboa
- R. Medzhitov
- Zhijian J. Chen
In Molecular Biology
- Satoshi Uematsu
- Peter S. Linsley
- Shizuo Akira
- Gabriel Lopez-Berestein
- J. Lieberman
- V. Hornung
- M. Manoharan
- D. Dykxhoorn
Citations in the corpus
- Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7 (2005, background): “Contradicting this concept is a report suggesting that transfection of siRNAs into cell lines results in PKR-dependent type I IFN respons”
- Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors (2005, background): “Although some questions remain about specificity and activation of off-target effect”
- Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras (2006, background): “A10 chimeras do not trigger interferon responses Various groups have reported that delivered siRNAs can potentially activate nonspecific inflammatory responses, leading to cellular toxicit”
- Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. (2005, background): “A more speculative notion is that intracellular complexes, such as RNP particles, or even small RNA, might activate the IFN pathway through intracellular TLR or via TLRindependent mechanisms (36).”
- Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. (2005, background): “Another level of questionable specificity of siRNA introduction lies in activation of the innate immune system. siRNA therapy has, in some circumstances, been shown to activate IFN (49, 50).”
- Impact of Protein Kinase PKR in Cell Biology: from Antiviral to Antiproliferative Action (2006, background): “However, experiments have to be carried out with caution, as PKR activation upon siRNA treatment has been reported as a potential nonspecific effect under certain circumstances (312, 329).”
- Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA (2005, background): “, and in vitro evidence suggests that siRNA can also activate this pathway under certain condition”
- Molecular mechanisms and potential therapeutical targets in Huntington's disease. (2010, background): “Finally, recent studies have highlighted the potential side effects of siRNAs, such as changes in expression of off-target genes (140, 278, 508), induction of cellular immunoreactive responses (532), or competition of exogenous RNA interference with endogenous, intracellular mRNA silencing systems (”